European Commission launches proposals for first Joint Technology Initiatives

The European Commission is now on the road to creating the first ever Europe-wide public-private partnerships to boost research and development, having adopted proposals for initiatives in two strategic industrial sectors.

The Commission presented two Joint Technology Initiatives (JTIs), worth approximately €5 billion, on embedded computing systems, to be known as ARTEMIS (Advanced Research and Technology for Embedded Intelligence and Systems), and on innovative medicines (Innovative Medicines Initiative).

The two JTIs will pool private sector investment with national and European public funding to create a single European-wide research programme that is driven by the needs of industry, and focused on clear joint technological and economic objectives.

"Europe needs a new approach to research in promising areas for our competitiveness and well-being," said EU Science and Research Commissioner Janez Potocnik.

"The proposals today show that the European Commission is committed to thinking differently where that is what Europe needs."

The novel JTIs will move away from the traditional approach of case-by-case public funding of projects, and head towards large scale research programmes dedicated to meeting the common strategic research targets of specific industrial sectors.

The European Commission hopes that the new bottom-up approach will stimulate European investment in research and development and build critical mass by uniting currently fragmented efforts.

ARTEMIS, will address the invisible technology (embedded systems) found in many machines today, ranging from cars, planes and mobile phones, energy networks and factories to washing machines and televisions.

Its research budget will total €2.7 billion over seven years, with around 60% of the budget expected to come from industry, €410 million from the Commission and €800 million from EU Member States.

The Innovative Medicines Initiative (IMI) will aim to support the development of new knowledge, tools and methods so that better and safer medicines can be made available on the market more quickly.

This programme will have €2 billion to invest over seven years. The Community contribution of ¿1 billion will go entirely to small and medium-sized enterprises (SMEs) and universities, for research that can be used by the pharmaceutical sector. In return, major companies will match this amount and involve these same SMEs and universities. The IMI will therefore contribute to increasing private investment in R&D, improving knowledge transfer between universities and business, and involving small business in European research.

Although there are substantial levels of public funding involved in JTIs, the Commission insists that the new research initiatives are designed to be as administratively fast, flexible and light as possible, with overheads being as low as between 1.5 and 4% of the total budget.

Also, the initiatives will be implemented through Joint Undertakings that will be established by Council Regulations on the basis of Article 171 of the EC Treaty.

Mr Potocnik said: "Each JTI will be managed by a Joint Undertaking, funded by both industry and the public sector (European and/or national). They will be established under Community law, a first for an organisation of this type. We have designed them to have the necessary flexibility to function as private/public partnerships while guaranteeing a sound implementation of Community funds."

The Commission's proposals for each JTI will be presented to the Competitiveness Council on 21 and 22 May, with the hope that the regulations will be adopted during the Portuguese Presidency, in time for both JTIs to start work early in 2008.

The next potential candidates for JTIs are in the fields of nano-electronics, clean skies (greening of aeronautics), hydrogen and fuel cells, and global monitoring for environment and security. Proposals are expected to follow soon.

"I don't think I can emphasise enough that what we are proposing today is truly ground-breaking. Seeing this through will require real commitment from all those involved: industry, Commission, Member States, European Parliament. It may not always be easy. But it is too important not to try, and not to give it everything we've got," the Commissioner concluded.

For further information, please visit:

Copyright ©European Communities, 2007
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Stanford Medicine Study Suggests Physici…

Artificial intelligence-powered chatbots are getting pretty good at diagnosing some diseases, even when they are complex. But how do chatbots do when guiding treatment and care after the diagnosis? For...

Adults don't Trust Health Care to U…

A study finds that 65.8% of adults surveyed had low trust in their health care system to use artificial intelligence responsibly and 57.7% had low trust in their health care...

AI Unlocks Genetic Clues to Personalize …

A groundbreaking study led by USC Assistant Professor of Computer Science Ruishan Liu has uncovered how specific genetic mutations influence cancer treatment outcomes - insights that could help doctors tailor...

The 10 Year Health Plan: What do We Need…

Opinion Article by Piyush Mahapatra, Consultant Orthopaedic Surgeon and Chief Innovation Officer at Open Medical. There is a new ten-year plan for the NHS. It will "focus efforts on preventing, as...

People's Trust in AI Systems to Mak…

Psychologists warn that AI's perceived lack of human experience and genuine understanding may limit its acceptance to make higher-stakes moral decisions. Artificial moral advisors (AMAs) are systems based on artificial...

Deep Learning to Increase Accessibility…

Coronary artery disease is the leading cause of death globally. One of the most common tools used to diagnose and monitor heart disease, myocardial perfusion imaging (MPI) by single photon...

AI Model can Read ECGs to Identify Femal…

A new AI model can flag female patients who are at higher risk of heart disease based on an electrocardiogram (ECG). The researchers say the algorithm, designed specifically for female patients...

New AI Tool Mimics Radiologist Gaze to R…

Artificial intelligence (AI) can scan a chest X-ray and diagnose if an abnormality is fluid in the lungs, an enlarged heart or cancer. But being right is not enough, said...

Relationship Between Sleep and Nutrition…

Diet and sleep, which are essential for human survival, are interrelated. However, recently, various services and mobile applications have been introduced for the self-management of health, allowing users to record...

DMEA 2025 - Innovations, Insights and Ne…

8 - 10 April 2025, Berlin, Germany. Less than 50 days to go before DMEA 2025 opens its doors: Europe's leading event for digital health will once again bring together experts...

To be Happier, Take a Vacation... from Y…

Today, nearly every American - 91% - owns a cellphone that can access the internet, according to the Pew Research Center. In 2011, only about one-third did. Another study finds...

Researchers Find Telemedicine may Help R…

Low-value care - medical tests and procedures that provide little to no benefit to patients - contributes to excess medical spending and both direct and cascading harms to patients. A...